StockWatch
·

Mukka Proteins Ltd Q2 FY27 Results

MUKKAQ2 FY27 Results
Filing
Result:Very Good· Market: Flat#Broad based#Margin expansion
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue508.873.9%108.1%
Total Income517.915.4%106.7%
Expenditure489.345.7%103.2%
PBT28.570.8%193.8%
Net Profit17.734.9%157.5%
OPM8.31%1.49pp0.16pp
NPM3.42%0.37pp0.67pp
EPS0.5315.9%165.0%
View full financials

Revenue +108% and PAT +158% YoY were driven by genuine core export-business growth (not one-offs), with NPM expanding to 3.42% from 2.75%, qualifying as a sector standout despite flat OPM and JV-driven dilution at the consolidated level.

Q2 FY-2027 RESULTS · MUKKA

Mukka Proteins: consolidated PAT up 157.5% YoY to ₹17.7 Cr on export surge, dips 4.9% QoQ on tax

PAT +157.53% YoY · revenue +108.06% · margins expanding

07 Nov 2026 · 3 min read
Revenue

₹508.87 Cr

+108.06% YoY

PAT (consolidated)

₹17.73 Cr

+157.53% YoY

Net margin

3.42%

+0.7pp YoY

EPS

₹0.53

Mukka Proteins' consolidated PAT came in at ₹17.73 Cr for Q2 FY27, up 157.5% YoY from ₹6.88 Cr, on revenue of ₹508.87 Cr, up 108.1% YoY from ₹244.58 Cr. Sequentially the picture is softer: revenue rose a modest 3.9% QoQ but PAT fell 4.9% QoQ from ₹18.63 Cr.

The scoreboard

Q2 FY-2027 vs prior quarters

Consolidated P&L, ₹ Crore
Q2 FY-2027QoQYoY
Revenue₹508.87 Cr+3.9%+108.1%
Expenses₹489.34 Cr+5.7%+103.2%
PAT₹17.73 Cr-4.87%+157.53%
Net margin3.42%-0.4pp+0.7pp
EPS₹0.53-15.9%+165%

The YoY story is a genuine net-margin expansion — NPM improved to 3.42% from 2.75% a year ago — while OPM was roughly steady (8.31% vs 8.47%). The QoQ dip, however, is not an operating story at all: PBT was virtually flat sequentially at ₹27.38 Cr versus ₹27.37 Cr in Q1 FY27. The entire sequential PAT decline traces to the tax line, where the effective rate jumped to ~35.3% from ~31.9% in Q1 (deferred tax nearly doubled to ₹4.54 Cr from ₹2.55 Cr). Standalone (parent-only) PAT grew ~196% YoY to ₹10.70 Cr — well ahead of the 157.5% consolidated growth — meaning subsidiaries and joint ventures collectively diluted group profit growth this quarter, consistent with the ₹1.19 Cr associates/JV share-of-loss booked (versus ₹0.45 Cr a year ago).

₹
21.8424.727.5630.4233.2829.5308-0408-1308-2409-0209-1109-16
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹29.53, up 7.3% over the past month of trading.

₹ Cr
010.1720.3530.521.59Q1 FY26rev ₹171 Cr6.88Q2 FY26rev ₹245 Cr27.25Q3 FY26rev ₹653 Cr21.36Q4 FY26rev ₹381 Cr18.63Q1 FY27rev ₹490 Cr17.73Q2 FY27rev ₹509 Cr
Quarterly consolidated PAT, ₹ Crore

No brokerage previews or consensus estimates for this quarter turned up in search — this is a micro-cap with no visible formal analyst coverage — so the print cannot be graded against street expectations, and management has issued no prior formal guidance on record either. Export sales drove the topline: consolidated revenue from outside India rose to ₹413.51 Cr from ₹141.36 Cr a year ago, while India revenue actually fell to ₹81.77 Cr from ₹94.72 Cr. That lines up with a cluster of export-facing approvals this quarter — US FDA facility registration (Oct 27) and a USDA NOP inputs attestation (Oct 6) — and a subsidiary that began commercial production in Oman on Oct 9, backed by a ₹73.58 Cr parent guarantee on its credit facility. The company also drew ₹11.75 Cr (25% upfront) of a ₹47 Cr convertible-warrant issue (2 crore warrants at ₹23.50 each) this quarter, funding a step-up in capex — consolidated gross block rose to ₹195.1 Cr from ₹163.9 Cr at FY26-end.

  • W1

    Effective tax rate: jumped to ~35.3% in Q2 FY27 from ~31.9% in Q1 FY27 — watch whether it normalizes in Q3

  • W2

    Oman subsidiary ramp-up after commercial production start (Oct 9, 2026), backed by a ₹73.58 Cr parent guarantee on its credit facility

  • W3

    Aqua Marine acquisition, now targeted for completion by January 2027 after being delayed from its original timeline

Figures in ₹ Million in source, converted to ₹ Crore (÷10); no exceptional items in either period. Consolidated PAT (₹17.73 Cr) includes ₹1.74 Cr non-controlling interest and a ₹1.19 Cr share-of-loss from associates/JVs; reported EPS (₹0.53) is computed on the ₹15.99 Cr profit attributable to owners, not total PAT.

Informational and educational content only. Not investment advice.